Method of inhibiting neurotrophin-receptor binding
View Patent ↗The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75 NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75 NTR comprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys 34 of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys 95 of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys 88 of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys 32 of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile 31 , Phe 101 and Phe 86 of nerve growth factor.
1. A compound of Formula 3 which is:
or a pharmaceutically acceptable salt thereof, wherein:
one of X 1 and X 2 is hydrogen and the other of X 1 and X 2 is selected from the group comprising of carbonyl; thiocarbonyl; ester; imino; amido; carboxylic acid; sulfonic acid; sulfinic acid; sulfamic acid; phosphonic acid; boronic acid; sulfate ester, hydroxyl; mercapto; cyano; cyanate; thiocyanate; isocyanate; isothiocyanate; carbonate; nitrate; nitro; alkylcarbonyl; alkylthiocarbonyl; alkoxycarbonyl; aminocarbonyl; halomethyl; dihalomethyl; trihalomethyl; and a halogen atom; and
R 1 is selected from the group consisting of a monocyclic aryl substituted with at least one acid functional group, a polycyclic aryl substituted with at least one acid functional group, a heteroaryl substituted with at least one acid functional group, a monosaccharide substituted with at least one acid functional group and an oligosaccharide substituted with at least one acid functional group, wherein the at least one acid functional group substituted on R 1 is selected from the group consisting of —CO 2 H; —SO 3 H; —SO 2 H; —PO 3 H 2 ; —OSO 3 H; -alkyl-CO 2 H; -alkyl-SO 3 H; -alkyl-SO 2 H; -alkyl-PO 3 H 2 and -alkyl-OSO 3 H and wherein the alkyl group is a C 1 –C 4 alkyl group.
2. The compound defined in claim 1 , wherein X 1 is hydrogen and X 2 is an electronegative atom or an electronegative group.
3. The compound defined in claim 1 , wherein X 2 is hydrogen and X 1 is an electronegative atom or an electronegative group.
4. The compound defined in claim 1 , wherein one of X 1 and X 2 is hydrogen and the other of X 1 and X 2 is —NO 2 .
5. A pharmaceutical composition comprising the compound defined in claim 1 , together with a pharmaceutically acceptable carrier.
6. The compound defined in claim 1 , wherein the compound of Formula 3 is 3-nitro-N-(p-carboxyphenyl)-1,8-naphthalimide or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition comprising the compound defined in claim 6 , together with a pharmaceutically acceptable carrier.
8. The compound defined in claim 1 , wherein the compound of Formula 3 is 3-nitro-N-(m-carboxyphenyl)-1,8-naphthalimide or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising the compound defined in claim 8 , together with a pharmaceutically acceptable carrier.
10. The compound defined in claim 1 , wherein the compound of Formula 3 is 3-nitro-N-(o-carboxyphenyl)-1,8-naphthalimide or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising the compound defined in claim 10 , together with a pharmaceutically acceptable carrier.
12. The compound defined in claim 1 , wherein the compound of Formula 3 is 3-nitro-N-(p-carboxyphenylmethyl)-1,8-naphthalimide or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising the compound defined in claim 12 , together with a pharmaceutically acceptable carrier.
14. The compound defined in claim 1 , wherein the compound of Formula 3 is 4-nitro-N-(p-carboxyphenyl)-1,8-naphthalimide or a pharmaceutically acceptable unit thereof.
15. A pharmaceutical composition comprising the compound defined in claim 14 , together with a pharmaceutically acceptable carrier.
16. The compound defined in claim 1 , wherein the compound of Formula 3 is 4-nitro-N-(m-carboxyphenyl)-1,8-naphthalimide or a pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition comprising the compound defined in claim 16 , together with a pharmaceutically acceptable carrier.
18. The compound defined in claim 1 , wherein the compound of Formula 3 is 4-nitro-N-(o-carboxyphenyl)-1,8-naphthalimide or a pharmaceutically acceptable salt thereof.
19. A pharmaceutical composition comprising the compound defined in claim 18 , together with a pharmaceutically acceptable carrier.